Interferon Gamma Release Assay and Tuberculin Skin Test Performance in Pregnant Women Living With and Without HIV. [PDF]
Kaplan SR +8 more
europepmc +1 more source
Astrocyte‐specific SHP1 deletion disrupts astrocyte–vascular interactions and compromises BBB integrity while enhancing STAT1‐dependent CXCL10 expression. These changes synergistically promote peripheral CD4+ and CD8+ T‐cell infiltration into the SDH. The infiltrating T cells secrete IFN‐γ, which in turn activates microglia.
Lan‐Xing Yi +7 more
wiley +1 more source
Eradicating latent tuberculosis: use of interferon gamma release assay and isoniazid/rifapentine in people living with HIV/AIDS. [PDF]
Monteiro MA +16 more
europepmc +1 more source
Comparison of interferon gamma release assay and CXCL9 gene expression assay for the detection of Mycobacterium bovis infection in African lions (Panthera leo). [PDF]
Gumbo R +7 more
europepmc +1 more source
A 3D‐printed interpenetrating Ti/Zn composite enables sustained Zn2+ release to regulate intracellular Ca2+ redistribution, preserve mitochondrial homeostasis, activate ERK/MAPK signaling, and promote M2 macrophage polarization, thereby enhancing osteoimmune‐mediated bone regeneration and peri‐implant osseointegration.
Wanyi Huang +7 more
wiley +1 more source
Screening for Latent Tuberculosis Across Chronic Kidney Disease Stages Using Interferon-Gamma Release Assay: Findings from a National Infectious Disease Institute in Thailand. [PDF]
Pongpirul W +4 more
europepmc +1 more source
Exposure to CS causes an elevation of AARS1 levels, which increases the levels of RUNX3 lactylation at the K193 site and increases protein levels of RUNX3 through inhibition of autolysosomal degradation. Elevated RUNX3 levels promote CD8+T cell activation and augment their cytotoxicity, which induces alveolar epithelial cell death and facilitates the ...
Ying Zhu +12 more
wiley +1 more source
Interferon gamma release assay and tuberculin skin test positivity in sarcoidosis
Sunil Vyas +4 more
doaj
Predictors of interferon-gamma release assay results and their association with COVID-19 infection outcomes. [PDF]
Kang SJW +3 more
europepmc +1 more source
This study shows that a PARP inhibitor combined with anlotinib, administered as bridging therapy, preconditions the tumor microenvironment to enhance the infiltration and antitumor activity of subsequently infused CAR‐T cells across preclinical ovarian cancer models, supporting bridging therapy as a promising strategy to address limited CAR‐T cell ...
Huayi Li +20 more
wiley +1 more source

